Literature DB >> 75060

Quantification of bleomycin pulmonary toxicity in mice by changes in lung hydroxyproline content and morphometric histopathology.

B I Sikic, D M Young, E G Mimnaugh, T E Gram.   

Abstract

Bleomycin treatment produced dose-dependent changes in lung collagen content and in several measurable histopathological parameters. NIH/Swiss mice were treated twice weekly for 6 weeks with bleomycin, 0, 1, 20, or 40 mg/kg s.c. The two highest doses produced mortalities of 35 and 100%, respectively, as well as loss of body weight and increase in lung wet weight. Lung hydroxyproline content, an index of collagen, increased to 40 to 50% above control levels at 6 and 8 weeks after initiation of treatment with bleomycin 20 mg/kg. Morphometric analysis was applied to the following parameters at light microscopy: number of intraalveolar macrophages and leukocytes, total pulmonary cell count, alveolar wall thickness, and percentage of consolidation of lung parenchyma. The two highest doses produced increases in all of these parameters as compared to controls. The most marked changes occurred in the number of intraalveolar cells, which in the group given 20 mg/kg rose to 150, 190, and 210% of controls at 4, 6, and 8 weeks. The lowest dose of bleomycin, 1 mg/kg twice weekly for 6 weeks, evoked no pulmonary or other toxicity by the parameters examined. This model of chronic pulmonary toxicity may be useful in analog development, in testing potential antidotes, and in examining the effects of other factors that might modify the pulmonary toxicity of bleomycin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 75060

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Titration of non-replicating adenovirus as a vector for transducing active TGF-beta1 gene expression causing inflammation and fibrogenesis in the lungs of C57BL/6 mice.

Authors:  G Sakuntala Warshamana; Derek A Pociask; Krishna J Fisher; Jing-Yao Liu; Patricia J Sime; Arnold R Brody
Journal:  Int J Exp Pathol       Date:  2002-08       Impact factor: 1.925

Review 2.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-dependent.

Authors:  P J Christensen; R E Goodman; L Pastoriza; B Moore; G B Toews
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

4.  Assessment of pulmonary and hematologic toxicities of liblomycin, a novel bleomycin analog.

Authors:  R A Newman; Z H Siddik; E L Travis; D Followill; W Ayele; T Burditt; I H Krakoff
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

5.  Prevention of bleomycin-induced fibrosing alveolitis with indomethacin: stereological studies on rat lungs.

Authors:  G Mall; P Zimmermann; I Siemens; A Burkhardt; H F Otto
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

6.  Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity.

Authors:  J S Lazo; C J Humphreys
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

7.  A comparison of the pulmonary toxicity and chemotherapeutic activity of bleomycin-BAPP to bleomycin and pepleomycin.

Authors:  E Ginsburg; T E Gram; M A Trush
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin.

Authors:  B A Teicher; J S Lazo; W W Merrill; A E Filderman; C M Rose
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Uptake of 67Ga in the lung of mice during bleomycin treatment.

Authors:  T Sasaki; S Kojima; A Kubodera
Journal:  Eur J Nucl Med       Date:  1984

10.  Tallysomycin S10b: experimental antitumor activity and toxicity.

Authors:  J E Schurig; W C Rose; R S Hirth; A Schlein; J B Huftalen; A P Florczyk; W T Bradner
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.